Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
InMed Pharmaceuticals ( (INM) ) just unveiled an update.
InMed Pharmaceuticals announced the presentation of new preclinical data from its INM-901 program at the Alzheimer’s Association International Conference 2025. The study, conducted on a 5xFAD mouse model, demonstrated that INM-901 shows promise in mitigating Alzheimer’s disease pathology through multiple mechanisms, including reducing neuroinflammation and promoting neuronal regeneration. These findings suggest that INM-901 could significantly impact the treatment landscape for Alzheimer’s disease, offering a multi-targeted therapeutic approach that addresses key pathological features of the condition.
Spark’s Take on INM Stock
According to Spark, TipRanks’ AI Analyst, INM is a Underperform.
InMed Pharmaceuticals’ overall stock score is primarily hindered by its financial performance and valuation concerns. The persistent operational losses and negative cash flows are significant risks. Technical analysis indicates a mildly bearish to neutral trend. The recent $5M private placement is a positive development, but it does not outweigh the broader financial challenges.
To see Spark’s full report on INM stock, click here.
More about InMed Pharmaceuticals
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. The company’s pipeline includes programs for the treatment of Alzheimer’s and other diseases with high unmet medical needs.
Average Trading Volume: 3,241,132
Technical Sentiment Signal: Sell
Current Market Cap: $5.29M
See more insights into INM stock on TipRanks’ Stock Analysis page.